The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation
Landmark clinical trials, such as the STEP programme for semaglutide published in The New England Journal of Medicine, have demonstrated that these medications can lead to average weight loss of 15% or more when combined with lifestyle changes, a level of efficacy previously achievable only through bariatric surgery
Glucagon Receptor Activity (The "GLP-3" Misnomer Explained) The glucagon receptor is the third lever
Semaglutide activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors
In an emergency, call 999
A prior study had shown that retatrutide and semaglutide reduced pancreatic tumor mass in mice, along with weight loss